Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.

CONTEXT Cholinesterase inhibitors are the primary treatment for the cognitive symptoms of Alzheimer disease (AD). Cholinergic dysfunction is also associated with neuropsychiatric and functional deficits, but results from randomized controlled trials of cholinesterase inhibitors are conflicting. OBJECTIVE To conduct a systematic review and meta-analysis to quantify the efficacy of cholinesterase inhibitors for neuropsychiatric and functional outcomes in patients with mild to moderate AD. DATA SOURCES We performed a literature search of trials using MEDLINE (January 1966-December 2001), Dissertations Abstracts On-line, PSYCHINFO, BIOSIS, PubMed, and the Cochrane Controlled Trials Register. We retrieved English- and non-English-language articles for review and collected references from bibliographies of reviews, original research articles, and other articles of interest. We searched for both published and unpublished trials, contacting researchers and pharmaceutical companies. STUDY SELECTION We included 29 parallel-group or crossover randomized, double-blind, placebo-controlled trials of outpatients who were diagnosed as having mild to moderate probable AD and were treated for at least 1 month with a cholinesterase inhibitor. Sixteen trials included neuropsychiatric and 18 included functional measures. DATA EXTRACTION Two investigators (N.H.T. and J.H.) independently extracted study methods, sources of bias, and outcomes. Neuropsychiatric outcomes were measured with the Neuropsychiatric Inventory (NPI, 0-120 points) and the Alzheimer Disease Assessment Scale, noncognitive (ADAS-noncog, 0-50 points) and were analyzed with the weighted mean difference method. Functional outcomes were measured with several activities of daily living (ADL) and instrumental activities of daily living (IADL) scales and analyzed with the standardized mean difference method. DATA SYNTHESIS For neuropsychiatric outcomes, 10 trials included the ADAS-noncog and 6 included the NPI. Compared with placebo, patients randomized to cholinesterase inhibitors improved 1.72 points on the NPI (95% confidence interval [CI], 0.87-2.57 points), and 0.03 points on the ADAS-noncog (95% CI, 0.00-0.05 points). For functional outcomes, 14 trials used ADL and 13 trials used IADL scales. Compared with placebo, patients randomized to cholinesterase inhibitors improved 0.1 SDs on ADL scales (95% CI, 0.00-0.19 SDs), and 0.09 SDs on IADL scales (95% CI, 0.01 to 0.17 SDs). There was no difference in efficacy among various cholinesterase inhibitors. CONCLUSIONS These results indicate that cholinesterase inhibitors have a modest beneficial impact on neuropsychiatric and functional outcomes for patients with AD. Future research should focus on how such improvements translate into long-term outcomes such as patient quality of life, institutionalization, and caregiver burden.

[1]  B. Gulanski,et al.  Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: A randomized, double-masked, placebo-controlled trial , 1999 .

[2]  P. Tariot,et al.  Measures of Psychiatric Symptoms in Alzheimer Patients: A Review , 1996, Alzheimer disease and associated disorders.

[3]  J. Colliver,et al.  Double-Blind, Placebo-Controlled Study of Metrifonate, an Acetylcholinesterase Inhibitor, for Alzheimer Disease , 1996, Alzheimer disease and associated disorders.

[4]  William R. Shadish,et al.  Combining estimates of effect size. , 1994 .

[5]  J. O'Brien,et al.  Quality of Life for People With Dementia Living in Residential and Nursing Home Care: The Impact of Performance on Activities of Daily Living, Behavioral and Psychological Symptoms, Language Skills, and Psychotropic Drugs , 2001, International Psychogeriatrics.

[6]  K. Rockwood,et al.  Assessing the Clinical Importance of Statistically Significant Improvement in Anti-Dementia Drug Trials , 2001, Neuroepidemiology.

[7]  D. Jeste,et al.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.

[8]  C. Lyketsos,et al.  Quality of life in dementia patients in long‐term care , 2000, International journal of geriatric psychiatry.

[9]  W. Hauser,et al.  Predictors of disease course in patients with probable Alzheimer's disease , 1987, Neurology.

[10]  Y. Agid,et al.  Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Commentary , 1998 .

[11]  A. Hofman,et al.  Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.

[12]  P. Whitehouse.  The cholinergic deficit in Alzheimer's disease. , 1998, The Journal of clinical psychiatry.

[13]  M. Esiri,et al.  Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex , 2001, Neurology.

[14]  I. Martinson,et al.  The frequency and troublesomeness of symptoms associated with Alzheimer's disease. , 1995, Journal of community health nursing.

[15]  W. Schmitt,et al.  Double-Blind, Randomized, Placebo-Controlled Clinical Trial on the Efficacy and Tolerability of a Physostigmine Patch in Patients with Senile Dementia of the Alzheimer Type , 1999, Pharmacopsychiatry.

[16]  M. Mega,et al.  The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. , 1999, Archives of neurology.

[17]  A Whitehead,et al.  Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. , 1998, JAMA.

[18]  S. Lewington,et al.  Tacrine for Alzheimer's disease (Withdrawn Paper. 1999, art. no. CD000202) , 2005 .

[19]  C. Pieper,et al.  Predictors of time to institutionalization of patients with Alzheimer's disease , 1997, Neurology.

[20]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[21]  G. Gharabawi,et al.  A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®) , 1999, European journal of neurology.

[22]  R F Woolson,et al.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. , 1992, The New England journal of medicine.

[23]  M. Oremus,et al.  Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Behavior and Mood Scales , 2000, Journal of geriatric psychiatry and neurology.

[24]  R. Koff,et al.  Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for quantitative synthesis in medicine , 1995 .

[25]  P. Antuono.  Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. , 1995, Archives of internal medicine.

[26]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[27]  B. Winblad,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.

[28]  W. Scott,et al.  Risk of institutionalization among community long-term care clients with dementia. , 1997, The Gerontologist.

[29]  B. Gulanski,et al.  The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. , 1999, The Journal of clinical psychiatry.

[30]  J. Colliver,et al.  Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study. , 1998, Alzheimer disease and associated disorders.

[31]  D. Coakley,et al.  BEHAVIOUR DISTURBANCE AND OTHER PREDICTORS OF CARER BURDEN IN ALZHEIMER'S DISEASE , 1997, International journal of geriatric psychiatry.

[32]  L. Thal,et al.  A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease , 1996, Neurology.

[33]  S. Gauthier,et al.  Assessment of functional changes in Alzheimer's disease. , 1990, Neuroepidemiology.

[34]  L. Thal,et al.  Chronic Oral Physostigmine Without Lecithin Improves Memory in Alzheimer's Disease , 1989, Journal of the American Geriatrics Society.

[35]  B. Imbimbo,et al.  A 6-Month, Double-Blind, Placebo-Controlled Trial of Eptastigmine in Alzheimer’s Disease , 2000, Dementia and Geriatric Cognitive Disorders.

[36]  G. Guyatt,et al.  Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease. , 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[37]  J. Cummings,et al.  Cholinesterase inhibitors: A new class of psychotropic compounds. , 2000, The American journal of psychiatry.

[38]  R. Rosenthal.  Parametric measures of effect size. , 1994 .

[39]  C. Lyketsos,et al.  Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. , 2002, JAMA.

[40]  M. Esiri,et al.  Cholinergic deficits contribute to behavioral disturbance in patients with dementia , 2000, Neurology.

[41]  Therese D. Pigott,et al.  Methods for handling missing data in research synthesis. , 1994 .

[42]  M. Crismon,et al.  Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease: A Double-blind, Placebo-Controlled Study , 1995 .

[43]  K. Davis,et al.  Functional Decline in Alzheimer's Disease: A Longitudinal Study , 1993, Journal of the American Geriatrics Society.

[44]  L. Thal,et al.  Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer’s disease , 1999, Neurology.

[45]  G A Chase,et al.  Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.

[46]  Y. Agid,et al.  EFFICACY AND TOLERABILITY OF RIVASTIGMINE IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER TYPE , 1998 .

[47]  S. Lewington,et al.  Tacrine for Alzheimer's disease , 1999 .

[48]  Jeffrey L. Cummings,et al.  The spectrum of behavioral changes in Alzheimer's disease , 1996, Neurology.

[49]  B. Gulanski,et al.  Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease , 1998, Neurology.

[50]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[51]  A double‐blind, placebo controlled, multicentre study of tacrine for alzheimer's disease , 1994 .

[52]  A. Hofman,et al.  Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.

[53]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[54]  I. McKeith,et al.  A multicentre, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild‐to‐moderate Alzheimer's disease: the MALT study , 1999, International journal of geriatric psychiatry.

[55]  C. Dyck,et al.  Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. , 2000, Archives of general psychiatry.

[56]  J. Coyle,et al.  Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis , 1981, Annals of neurology.

[57]  P. Tariot,et al.  Placebo-controlled study of divalproex sodium for agitation in dementia. , 2001, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[58]  M. Tsolaki,et al.  Rivastigmine for Alzheimer's disease. , 2000, The Cochrane database of systematic reviews.

[59]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .

[60]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[61]  H. Petit,et al.  A double‐blind, placebo‐controlled, enriched population study of tacrine in patients with Alzheimer's disease , 1995, European journal of neurology.

[62]  Velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled trial , 2005, Journal of Neural Transmission.

[63]  B. Gulanski,et al.  Metrifonate treatment of the cognitive deficits of Alzheimer's disease , 1998, Neurology.

[64]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[65]  L. Thal,et al.  A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer’s disease , 1999, Neurology.

[66]  Martin R. Farlow,et al.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.

[67]  J. Mintzer,et al.  Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial , 2001, Journal of neurology, neurosurgery, and psychiatry.

[68]  H. Beppu,et al.  Donepezil for mild and moderate Alzheimer's disease. , 2000 .

[69]  L. Thal,et al.  A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease. , 1998, Alzheimer disease and associated disorders.